Patents Assigned to KLINGE BIOPHARMA GMBH
  • Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
    Patent number: 11666632
    Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.
    Type: Grant
    Filed: February 26, 2022
    Date of Patent: June 6, 2023
    Assignees: FORMYCON AG, SIO2 MEDICAL PRODUCTS, INC., KLINGE BIOPHARMA GMBH
    Inventors: Carsten Brockmeyer, Christopher Weikart, Murray Stephen Bennett, Jean-Pierre Giraud, Thomas Strungmann
  • Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
    Patent number: 11298405
    Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: April 12, 2022
    Assignees: FORMYCON AG, SIO2 MEDICAL PRODUCTS, INC., KLINGE BIOPHARMA GMBH
    Inventors: Carsten Brockmeyer, Christopher Weikart, Murray Stephen Bennett, Jean-Pierre Giraud, Thomas Strungmann